Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
108
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Nkarta Inc market cap is $81.38M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Nkarta Inc 52 week high is $3.72 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Nkarta Inc 52 week low is $1.11 as of November 22, 2026.
Nkarta Inc stock price today is $1.14.
Nkarta Inc stock price yesterday was $1.12.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Nkarta Inc's P/E ratio is -0.65.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Nkarta Inc P/B ratio is 0.3772.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Nkarta Inc 50-day moving average is $2.02.